Value-Based Pricing: L’Enfant Terrible?

PharmacoEconomics

Volumn 36, Issue 1, 2018, Pages 5-6

  Garner, Sarah ^a   Rintoul, Andrew ^a   Hill, Suzanne R ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

SOFOSBUVIR;

BIOMEDICAL TECHNOLOGY ASSESSMENT; BUDGET; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG INDUSTRY; ECONOMIC EVALUATION; GROSS NATIONAL PRODUCT; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HEPATITIS C; HIGH INCOME COUNTRY; HUMAN; LETTER; LOW INCOME COUNTRY; ORGANIZATION; PATIENT CARE; POLICY; PREVALENCE; PRIORITY JOURNAL; PRIVATE SECTOR; REIMBURSEMENT; THERAPY EFFECT; VALUE BASED PRICING; WORLD HEALTH ORGANIZATION; COST;

COSTS AND COST ANALYSIS;

EID: 85038622635     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-017-0567-4     Document Type: Letter

References (11)

1. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2008;373(9659):240–9. doi:10.1016/S0140-6736(08)61762-6.
2. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, Hill S. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016. doi:10.1371/journal.pmed.1002032.
3. Towse A, Barnsley P. Approaches to identifying, measuring, and aggregating elements of value. Int J Technol Assess Health Care. 2013;29(4):360–4. doi:10.1017/S0266462313000524.
4. Neyt M. Value-based pricing: do not throw away the baby with the bath water. PharmacoEconomics. 2017. doi:10.1007/s40273-017-0566-5.
5. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 2000;283(16):2116–21.
6. Yong JHE, Beca J, Hoch JS. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada. PharmacoEconomics. 2013;31(3):229–36. doi:10.1007/s40273-012-0022-5.
7. Summary of a workshop to inform the research agenda on improving cross-sector comparisons using QALYs and other measures. London: National Institute for Health and Care Excellence. https://www.nice.org.uk/Media/Default/About/what-we-do/science-policy-and-research/beyond_qaly_workshop_report.pdf. Accessed 3 Aug 2017.
8. Bertram MY, Lauer JA, de Joncheere K, Edejer T, Hutubessy R, Kieny MP, Hill SR. Cost-effectiveness thresholds: pros and cons. Bull World Health Org. 2016;94:925–30. doi:10.2471/BLT.15.164418.
9. Garner S. How does NICE value innovation? Drug Dev Res. 2010;71:449–56. doi:10.1002/ddr.20423.
10. Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for universal health coverage. Lancet. 2017;389:403–76.
11. World Health Organisation. FAIR PRICING FORUM 2017 MEETING REPORT. 2017. http://www.who.int/medicines/access/fair_pricing/FairPricingForum2017MeetingReport.pdf?ua=1. Accessed 7 Nov 2017.